Fate Therapeutics, Inc. (FATE) vs Standard BioTools Inc. (LAB)
A side-by-side comparison of Fate Therapeutics, Inc. and Standard BioTools Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FATE
Fate Therapeutics, Inc.
$2.29HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
LAB
Standard BioTools Inc.
$0.72HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — FATE vs LAB
growth of $100 · dividends reinvested · last 10yFATE -18.2% (-2.0%/yr)LAB -90.5% (-20.9%/yr)FATE compounded faster over this window
Log scale — wide-divergence pair
FATE LAB
FATE vs LAB: by the numbers
- •LAB is the larger company ($283M vs $267M market cap).
- •Both run net losses; LAB's is the smaller (-103.29% vs -1941.09% net margin).
- •Both shrank revenue over the past five years; LAB's decline was smaller (-10.62% vs -32.98% CAGR).
Metrics side by side
Valuation
| Metric | FATE | LAB |
|---|---|---|
| P/S ratio | 41.12 | 3.34 |
| P/B ratio | 1.74 | 0.52 |
Profitability
| Metric | FATE | LAB |
|---|---|---|
| Gross margin | -94.12% | 49.14% |
| Operating margin | -2222.45% | -109.34% |
| Net margin | -1941.09% | -103.29% |
| ROE | -82.12% | -16.18% |
| ROIC | -58.72% | -14.06% |
Growth (annualized)
| Metric | FATE | LAB |
|---|---|---|
| Revenue CAGR (5Y) | -32.98% | -10.62% |
| Total return CAGR (5Y) | -46.86% | -32.98% |
Frequently asked
- Which has grown faster, FATE or LAB?
- Neither grew: over the past five years both shrank revenue, with LAB's decline the smaller — FATE at a -32.98% CAGR versus LAB at -10.62%.
- How have FATE and LAB total returns compared?
- Over the past 10 years, FATE delivered -2.31% and LAB delivered -20.93% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.